Gamal, Nesrine <br/><br/>
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.  [electronic resource] 

 -  Expert review of anti-infective therapy  Mar 2015 
 - 295-304 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1744-8336 
<br/><br/><label>Standard No.: </label>10.1586/14787210.2015.1001746  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Anilides--therapeutic use<br/>Antiviral Agents--therapeutic use<br/>Carbamates--therapeutic use<br/>Carcinoma, Hepatocellular--virology<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Cyclopropanes<br/>Drug Interactions<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Cirrhosis--virology<br/>Liver Neoplasms--virology<br/>Macrocyclic Compounds--therapeutic use<br/>Proline--analogs & derivatives<br/>Protease Inhibitors--therapeutic use<br/>RNA, Viral<br/>Randomized Controlled Trials as Topic<br/>Ribavirin--therapeutic use<br/>Ritonavir--therapeutic use<br/>Sulfonamides--therapeutic use<br/>Uracil--analogs & derivatives<br/>Valine